You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 825 α-CD38 therapy reverses α-PD1 resistance when used in a proper biologic schedule; explaining and overcoming previous failures of the combination in clinical trials

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
825 α-CD38 therapy reverses α-PD1 resistance when used in a proper biologic schedule; explaining and overcoming previous failures of the combination in clinical trials
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address